Market Overview

US Stock Futures Slide Ahead Of GDP Data

Share:
US Stock Futures Slide Ahead Of GDP Data

Pre-open movers

US stock futures traded lower in early pre-market trade. GDP data for the first quarter will be released at 8:30 a.m. ET. Futures for the Dow Jones Industrial Average tumbled 54 points to 18,013.0, while the Standard & Poor's 500 index futures fell 4.55 points to 2,111.95. Futures for the Nasdaq 100 index slipped 8.95 points to 4,532.30.

A Peek Into Global Markets

European markets were mostly lower today, with the Spanish Ibex Index dropping 0.89 percent, STOXX Europe 600 Index falling 0.34 percent and German DAX 30 index dropping 0.88 percent. French CAC 40 Index slipped 0.45 percent and London's FTSE 100 Index rose 0.29 percent.

In Asian markets, Japan's Nikkei Stock Average rose 0.28 percent, Hong Kong's Hang Seng Index gained 0.26 percent, China's Shanghai Composite Index climbed 2.48 percent and India's BSE Sensex fell 0.27 percent.

Broker Recommendation
Analysts at Jefferies upgraded Electronic Arts Inc. (NASDAQ: EA) from Hold to Buy.

Electronic Arts shares gained 0.75 percent to $67.08 in pre-market trading.

Breaking news

  • Lennar Corporation (NYSE: LEN) reported stronger-than-expected results for its fiscal second quarter. To read the full news, click here.
  • Celator Pharmaceuticals, Inc. (NASDAQ: CPXX) today announced final induction response rate results in the Phase 3 study comparing CPX-351 liposome injection to the standard of care regimen, referred to as 7+3, in patients with untreated high-risk acute myeloid leukemia. To read the full news, click here.
  • Pattern Energy Group Inc. (NASDAQ: PEGI) today announced the addition of four wind power projects and two solar power projects to its list of identified Right of First Offer projects from Pattern Energy Group LP. To read the full news, click here.
  • AbbVie (NYSE: ABBV) today announced TURQUOISE-III study results demonstrating 100 percent sustained virologic response at 12 weeks post-treatment in genotype 1b chronic hepatitis C virus infected adult patients with compensated liver cirrhosis.1 Patients received 12 weeks of VIEKIRAX® + EXVIERA® without ribavirin. To read the full news, click here.
 

Related Articles

View Comments and Join the Discussion!

Posted-In: Jefferies US Stock FuturesNews Eurozone Futures Global Pre-Market Outlook Markets